

-69-

internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1-dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from

-70-

commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

Oligonucleotide Analysis - 96 Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 5 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis,

-71-

Ribonuclease protection assays, or RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum ((Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

-72-

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

MCF7:

The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection (Manassas, VA). MCF-7 cells were routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds:

When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μ L OPTI-MEMTM-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μ L of OPTI-MEMTM-1 containing 3.75 μ g/mL LIPOFECTINTM (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control

-73-

oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control

5 oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for
10 ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf
15 mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

20

Example 10

Analysis of oligonucleotide inhibition of mucin 1, transmembrane expression

Antisense modulation of mucin 1, transmembrane expression
25 can be assayed in a variety of ways known in the art. For example, mucin 1, transmembrane mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be
30 performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1,
35 pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons,

-74-

Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of mucin 1, transmembrane can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to mucin 1, transmembrane can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-

-75-

4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM
5 vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times
10 with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated
15 on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

20 **Example 12**

Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown
25 on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 150 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The
30 samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500 μ L of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for 15 minutes and the vacuum was
35 again applied for 1 minute. An additional 500 μ L of Buffer RW1

-76-

was added to each well of the RNEASY 96™ plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and
5 the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 µL water
10 into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the
15 plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

20 Real-time Quantitative PCR Analysis of mucin 1, transmembrane mRNA Levels

Quantitation of mucin 1, transmembrane mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster
25 City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is
30 completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye
35 (e.g., FAM, obtained from either Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g.,

-77-

TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen, Carlsbad, CA. RT-PCR reactions were carried out by adding 20 µL PCR cocktail

-78-

(2.5x PCR buffer (-MgCl₂), 6.6 mM MgCl₂, 375 µM each of dATP, dCTP, dGTP and dTTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96 well plates containing 30 µL total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, Analytical Biochemistry, 1998, 265, 368-374.

In this assay, 170 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 µL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human mucin 1, transmembrane were designed to hybridize to a human mucin 1, transmembrane sequence, using published sequence information (GenBank accession number NM_002456.1, incorporated herein as SEQ ID NO:3). For human mucin 1, transmembrane the PCR primers were: forward primer: TGACTCTGGCCTTCCGAGAA (SEQ ID NO: 4) reverse primer: GCTGCTTCCGTTTTATACTGATTG (SEQ ID NO: 5) and the PCR probe was: FAM-TACCATCAATGTCCACGACGTGGAGACA-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human

-79-

GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:7)

reverse primer: GAAGATGGTGATGGGATTTTC (SEQ ID NO:8) and the PCR

probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3' (SEQ ID NO: 9)

5 where JOE (PE-Applied Biosystems, Foster City, CA) is the
fluorescent reporter dye) and TAMRA (PE-Applied Biosystems,
Foster City, CA) is the quencher dye.

10 **Example 14**

Northern blot analysis of mucin 1, transmembrane mRNA levels

Eighteen hours after antisense treatment, cell monolayers
were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-
TEST "B" Inc., Friendswood, TX). Total RNA was prepared
15 following manufacturer's recommended protocols. Twenty
micrograms of total RNA was fractionated by electrophoresis
through 1.2% agarose gels containing 1.1% formaldehyde using a
MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was
transferred from the gel to HYBOND™-N+ nylon membranes (Amersham
20 Pharmacia Biotech, Piscataway, NJ) by overnight capillary
transfer using a Northern/Southern Transfer buffer system (TEL-
TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by
UV visualization. Membranes were fixed by UV cross-linking
using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La
25 Jolla, CA) and then probed using QUICKHYB™ hybridization
solution (Stratagene, La Jolla, CA) using manufacturer's
recommendations for stringent conditions.

To detect human mucin 1, transmembrane, a human mucin 1,
transmembrane specific probe was prepared by PCR using the
30 forward primer TGA CTCTGGCCTTCCGAGAA (SEQ ID NO: 4) and the
reverse primer GCTGCTTCCGTTTATACTGATTG (SEQ ID NO: 5). To
normalize for variations in loading and transfer efficiency
membranes were stripped and probed for human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

35 Hybridized membranes were visualized and quantitated using
a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular
Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels

-80-

in untreated controls.

Example 15

5 **Antisense inhibition of human mucin 1, transmembrane expression
by chimeric phosphorothioate oligonucleotides having 2'-MOE
wings and a deoxy gap**

In accordance with the present invention, a series of
oligonucleotides were designed to target different regions of
10 the human mucin 1, transmembrane RNA, using published sequences
(GenBank accession number NM_002456.1, representing the main
mRNA of mucin 1, transmembrane, incorporated herein as SEQ ID
NO: 3; GenBank accession number AF125525.1, representing the
variant MUC1/Y, incorporated herein as SEQ ID NO: 10; GenBank
15 accession number AF348143.1, representing a variant of mucin 1,
transmembrane herein designated MUC1-II, incorporated herein as
SEQ ID NO: 11; GenBank accession number AI834269.1, representing
a variant of mucin 1, transmembrane herein designated MUC1-III,
the complement of which is incorporated herein as SEQ ID NO: 12;
20 GenBank accession number AW369441.1, representing a variant of
mucin 1, transmembrane herein designated MUC1-IV, incorporated
herein as SEQ ID NO: 14; GenBank accession number BG774910.1,
representing a variant of mucin 1, transmembrane herein
designated MUC1-V, incorporated herein as SEQ ID NO: 16; GenBank
25 accession number J05581.1, representing a variant of mucin 1,
transmembrane herein designated MUC1-VI, incorporated herein as
SEQ ID NO: 17; GenBank accession number M31823.1, representing a
variant of mucin 1, transmembrane herein designated MUC1-VII,
incorporated herein as SEQ ID NO: 18; GenBank accession number
30 M61170, representing a genomic sequence of mucin 1,
transmembrane, incorporated herein as SEQ ID NO: 19; GenBank
accession number U60259.1, representing the variant MUC1/X,
incorporated herein as SEQ ID NO: 20; and GenBank accession
number Z17325.1, representing the variant MUC1/D, incorporated
35 herein as SEQ ID NO: 21). The oligonucleotides are shown in
Table 1. "Target site" indicates the first (5'-most) nucleotide
number on the particular target sequence to which the
oligonucleotide binds. All compounds in Table 1 are chimeric

-81-

oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human mucin 1, transmembrane mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of human mucin 1, transmembrane mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
199396	5'UTR	3	8	gaacagattcaagcagccag	0	22
199397	Start Codon	3	49	cccgggtgtcatggtggtggt	58	23
199398	Start Codon	3	52	gtgcccgggtgtcatggtggt	58	24
199399	Coding	3	65	gaaaggagactgggtgcccg	54	25
199400	Coding	3	105	ctgtaacaactgtaagcact	41	26
199401	Coding	3	107	acctgtaacaactgtaagca	53	27
199402	Coding	3	187	tcagtagagctgggcactga	55	28
199403	Coding	3	196	gcattcttctcagtagagct	77	29
199404	Coding	3	197	agcattcttctcagtagagc	50	30
199405	Coding	3	210	tggtcatactcacagcattc	42	31
199406	Coding	3	214	ctgctgggtcatactcacagc	56	32
199407	Coding	3	227	gctggagagtacgctgctgg	57	33
199408	Coding	3	344	tgggaccgaggtgacatcct	65	34
199409	Coding	3	694	gtgacattgtggactggagg	55	35
199410	Coding	3	697	gaggtgacattgtggactgg	57	36
199411	Coding	3	704	tgaggccgaggtgacattgt	54	37
199412	Coding	3	829	gtggtaggagtatcagagtg	53	38
199413	Coding	3	835	gcaagggtggtaggagtatc	50	39
199414	Coding	3	860	ggcatcagtccttggtgctat	53	40
199415	Coding	3	940	gagaccccagtagacaactg	24	41
199416	Coding	3	997	tcttccagagaggaattaaa	41	42
199417	Coding	3	1037	aatgtctctctgcagctctt	41	43
199418	Coding	3	1042	tcagaaatgtctctctgcag	54	44
199419	Coding	3	1056	tctgcaaaaacatttcagaa	45	45

199420	Coding	3	1065	gtttataaatctgcaaaaac	39	46
199421	Coding	3	1091	attggagaggcccagaaaac	41	47
199422	Coding	3	1095	taatattggagaggcccaga	50	48
199423	Coding	3	1100	gaacttaatatattggagaggc	48	49
199424	Coding	3	1112	agatcctggcctgaacttaa	53	50
199425	Coding	3	1115	cacagatcctggcctgaact	49	51
199426	Coding	3	1168	acgtcgtggacattgatggt	84	52
199427	Coding	3	1217	gttatatcgagaggctgctt	50	53
199428	Coding	3	1225	atcgtcagggttatatcgaga	47	54
199429	Coding	3	1251	gcacatcactcacgctgacg	50	55
199430	Coding	3	1268	ggcagagaaaaggaaatggca	46	56
199431	Coding	3	1371	gcagacagccaaggcaatg	47	57
199432	Coding	3	1397	ctgcccgtagttctttcggc	43	58
199433	Coding	3	1412	tggaaagatgtccagctgcc	41	59
199434	Coding	3	1499	gctacgatcggtagctgtag	52	60
199435	Coding	3	1540	aggctgctgccaccattacc	59	61
199436	Coding	3	1582	aagttggcagaagtggctgc	42	62
199437	Stop Codon	3	1586	ctacaagttggcagaagtgg	35	63
199438	Stop Codon	3	1594	acgtgccctacaagttggc	57	64
199439	3'UTR	3	1606	gctcagagggcgacgtgcc	36	65
199440	3'UTR	3	1617	ctggccactcagctcagagg	56	66
199441	3'UTR	3	1622	actggctggccactcagctc	55	67
199442	3'UTR	3	1630	ggaatggcactggctggcca	60	68
199443	3'UTR	3	1635	ggagtggaaatggcactggct	56	69
199444	Coding	10	141	aggaattaaaagcattcttc	7	70
199445	Coding	11	174	cagtagacaaagcattcttc	40	71
199446	Coding	11	297	gacagacagccatttcagaa	80	72
199447	Exon: Exon Junction	12	49	catcactcactgaacttaat	1	73
199448	Intron 6	19	5327	tttgggtttttccaagtacc	83	74
199449	Intron 6	19	5436	catagtctcctcccaggcct	44	75
199450	Intron 6	19	5588	cattttgcctctgggtgcaa	49	76
199451	Exon: Exon Junction	14	160	cagccccagacatttcagaa	21	77
199452	Intron 1	19	3289	ttctctctgcccataaggcct	42	78
199453	Intron 1	19	3426	gggtcttttatgaaggaaaa	43	79
199454	Exon: Exon Junction	16	455	acatcactcacatttcagaa	62	80
199455	3'UTR	17	1776	accacgtttttattcagtcca	65	81
199456	Coding	18	115	gctgtggttagctgtaagcac	38	82
199457	Coding	20	175	gtgctgggatagcattcttc	15	83
199458	Coding	20	245	agagtcaattgtaccaccac	2	84
199459	Coding	21	122	ttttctccacctgtaagcac	18	85
199460	Intron: Exon Junction	19	3489	cctgtaacaactgttgcggg	32	86
199461	Intron: Exon	19	3498	tgaccagaacctgtaacaac	38	87

-83-

	Junction					
199462	Exon 2d	19	3530	tctcctttttctccacctggg	49	88
199463	Exon 2d	19	3571	ctcagtagagctgggcactg	47	89
199464	Exon 2d	19	3590	tcatactcacagcattcttc	42	90
199465	Exon: Intron Junction	19	3973	agagcctgaggccgaggtga	58	91
199466	Intron: Exon Junction	19	4201	gaccccagtagacaactggg	20	92
199467	Intron: Exon Junction	19	4250	aggaattaaactggaggttt	55	93
199468	Exon 3d	19	4269	gtgctgggatcttccagaga	61	94
199469	Intron: Exon Junction	19	4621	atcctggcctggtcacaggg	39	95
199470	Exon 5	19	4936	cagccccagactgggcagag	41	96
199471	Intron 6	19	5449	ggcccttttcttccatagtc	55	97
199472	Intron 6	19	5889	ccacctggagtgggtttcca	42	98
199473	Intron 6	19	5956	aaagccgagagaggaggtc	51	99

As shown in Table 1, SEQ ID NOs 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 66, 67, 68, 69, 72, 74, 75, 76, 78, 79, 80, 81, 88, 89, 90, 91, 93, 94, 96, 97, 98 and 99 demonstrated at least 41% inhibition of human mucin 1, transmembrane expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

15 **Example 16**

Western blot analysis of mucin 1, transmembrane protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to mucin 1, transmembrane is used,

-84-

with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

5

Example 17**Targeting of individual oligonucleotides to specific variants of mucin 1, transmembrane**

It is advantageous to selectively inhibit the expression of one or more variants of mucin 1, transmembrane. Consequently, in one embodiment of the present invention are oligonucleotides that selectively target, hybridize to, and specifically inhibit one or more, but fewer than all of the variants of mucin 1, transmembrane. A summary of the target sites of the variants is shown in Table 2 and includes Genbank accession number NM_002456.1, representing mucin 1, transmembrane (MUC1), incorporated herein as SEQ ID NO: 3; Genbank accession number AF125525.1, representing MUC1/Y, incorporated herein as SEQ ID NO: 10; Genbank accession number AF348143.1, representing MUC1-II, incorporated herein as SEQ ID NO: 11; Genbank accession number AI834269.1, representing MUC1-III, incorporated herein as SEQ ID NO: 12; Genbank accession number AW369441.1, representing MUC1-IV, incorporated herein as SEQ ID NO: 14; Genbank accession number BG774910.1, representing MUC1-V, incorporated herein as SEQ ID NO: 16; Genbank accession number J05581.1, representing MUC1-VI, incorporated herein as SEQ ID NO: 17; Genbank accession number M31823.1, representing MUC1-VII, incorporated herein as SEQ ID NO: 18; Genbank accession number U60259.1, representing MUC1/X, incorporated herein as SEQ ID NO: 20; Genbank accession number Z17325.1, representing MUC1/D, incorporated herein as SEQ ID NO: 21; Genbank accession number S81781.1, representing the variant MUC1/A, incorporated herein as SEQ ID NO: 100; Genbank accession number M32738.1, representing the variant MUC1/REP, incorporated herein as SEQ ID NO: 101; Genbank accession number M35093.1, representing the variant MUC1/SEC, incorporated herein as SEQ ID NO: 102; Genbank accession number U60261.1, representing the variant MUC1/Z, incorporated herein as SEQ ID NO: 103; Genbank accession number Z17324.1, representing the

-85-

variant MUC1/C, incorporated herein as SEQ ID NO: 104; Genbank accession number BF876382.1, representing a variant of mucin 1, transmembrane herein designated MUC1-VIII, incorporated herein as SEQ ID NO: 105; Genbank accession number BG541121.1, representing a variant of mucin 1, transmembrane herein designated MUC1-IX, incorporated herein as SEQ ID NO: 106; Genbank accession number AL046435.1, representing a variant of mucin 1, transmembrane herein designated MUC1-X, incorporated herein as SEQ ID NO: 107.

10

Table 2

Targeting of individual oligonucleotides to specific variants of mucin 1, transmembrane

ISIS #	OLIGO SEQ ID NO.	TARGET SITE	VARIANT	VARIANT SEQ ID NO.
199396	22	8	MUC1	3
199397	23	49	MUC1	3
199397	23	16	MUC1-II	11
199397	23	64	MUC1-VI	17
199397	23	58	MUC1-VII	18
199397	23	17	MUC1/X	20
199397	23	65	MUC1/D	21
199397	23	1	MUC1/A	100
199397	23	42	MUC1/REP	101
199397	23	776	MUC1/SEC	102
199397	23	17	MUC1/Z	103
199397	23	65	MUC1/C	104
199397	23	59	MUC1-IX	106
199398	24	52	MUC1	3
199398	24	19	MUC1-II	11
199398	24	67	MUC1-VI	17
199398	24	61	MUC1-VII	18
199398	24	20	MUC1/X	20
199398	24	68	MUC1/D	21
199398	24	4	MUC1/A	100
199398	24	45	MUC1/REP	101
199398	24	779	MUC1/SEC	102
199398	24	20	MUC1/Z	103
199398	24	68	MUC1/C	104
199398	24	62	MUC1-IX	106
199399	25	65	MUC1	3
199399	25	8	MUC1/Y	10
199399	25	32	MUC1-II	11
199399	25	80	MUC1-VI	17
199399	25	74	MUC1-VII	18
199399	25	33	MUC1/X	20

199399	25	81	MUC1/D	21
199399	25	17	MUC1/A	100
199399	25	58	MUC1/REP	101
199399	25	792	MUC1/SEC	102
199399	25	33	MUC1/Z	103
199399	25	81	MUC1/C	104
199399	25	75	MUC1-IX	106
199400	26	105	MUC1	3
199400	26	72	MUC1-II	11
199400	26	120	MUC1-VI	17
199400	26	73	MUC1/X	20
199400	26	73	MUC1/Z	103
199401	27	107	MUC1	3
199401	27	74	MUC1-II	11
199401	27	122	MUC1-VI	17
199401	27	75	MUC1/X	20
199401	27	75	MUC1/Z	103
199402	28	187	MUC1	3
199402	28	121	MUC1/Y	10
199402	28	154	MUC1-II	11
199402	28	202	MUC1-VI	17
199402	28	223	MUC1-VII	18
199402	28	155	MUC1/X	20
199402	28	166	MUC1/A	100
199402	28	207	MUC1/REP	101
199402	28	1413	MUC1/SEC	102
199402	28	155	MUC1/Z	103
199402	28	346	MUC1-VIII	105
199402	28	224	MUC1-IX	106
199403	29	196	MUC1	3
199403	29	130	MUC1/Y	10
199403	29	163	MUC1-II	11
199403	29	211	MUC1-VI	17
199403	29	232	MUC1-VII	18
199403	29	164	MUC1/X	20
199403	29	175	MUC1/A	100
199403	29	216	MUC1/REP	101
199403	29	1422	MUC1/SEC	102
199403	29	164	MUC1/Z	103
199403	29	355	MUC1-VIII	105
199403	29	233	MUC1-IX	106
199404	30	197	MUC1	3
199404	30	131	MUC1/Y	10
199404	30	164	MUC1-II	11
199404	30	212	MUC1-VI	17
199404	30	233	MUC1-VII	18
199404	30	165	MUC1/X	20
199404	30	176	MUC1/A	100
199404	30	217	MUC1/REP	101
199404	30	1423	MUC1/SEC	102
199404	30	165	MUC1/Z	103
199404	30	356	MUC1-VIII	105
199404	30	234	MUC1-IX	106

199405	31	210	MUC1	3
199405	31	225	MUC1-VI	17
199405	31	246	MUC1-VII	18
199405	31	189	MUC1/A	100
199405	31	230	MUC1/REP	101
199405	31	1436	MUC1/SEC	102
199405	31	369	MUC1-VIII	105
199406	32	214	MUC1	3
199406	32	229	MUC1-VI	17
199406	32	250	MUC1-VII	18
199406	32	193	MUC1/A	100
199406	32	234	MUC1/REP	101
199406	32	1440	MUC1/SEC	102
199406	32	373	MUC1-VIII	105
199407	33	227	MUC1	3
199407	33	242	MUC1-VI	17
199407	33	263	MUC1-VII	18
199407	33	206	MUC1/A	100
199407	33	247	MUC1/REP	101
199407	33	1453	MUC1/SEC	102
199407	33	386	MUC1-VIII	105
199408	34	344	MUC1	3
199408	34	359	MUC1-VI	17
199408	34	380	MUC1-VII	18
199408	34	364	MUC1/REP	101
199408	34	1570	MUC1/SEC	102
199409	35	694	MUC1	3
199409	35	93	MUC1-V	16
199409	35	589	MUC1-VI	17
199409	35	1800	MUC1/SEC	102
199410	36	697	MUC1	3
199410	36	96	MUC1-V	16
199410	36	592	MUC1-VI	17
199410	36	1803	MUC1/SEC	102
199411	37	704	MUC1	3
199411	37	103	MUC1-V	16
199411	37	599	MUC1-VI	17
199411	37	1810	MUC1/SEC	102
199412	38	829	MUC1	3
199412	38	228	MUC1-V	16
199412	38	724	MUC1-VI	17
199412	38	1935	MUC1/SEC	102
199413	39	835	MUC1	3
199413	39	234	MUC1-V	16
199413	39	730	MUC1-VI	17
199413	39	1941	MUC1/SEC	102
199414	40	860	MUC1	3
199414	40	259	MUC1-V	16
199414	40	755	MUC1-VI	17
199414	40	1966	MUC1/SEC	102
199415	41	940	MUC1	3
199415	41	44	MUC1-IV	14
199415	41	339	MUC1-V	16

-88-

199415	41	835	MUC1-VI	17
199415	41	2046	MUC1/SEC	102
199416	42	997	MUC1	3
199416	42	151	MUC1/Y	10
199416	42	238	MUC1-II	11
199416	42	101	MUC1-IV	14
199416	42	396	MUC1-V	16
199416	42	892	MUC1-VI	17
199416	42	2103	MUC1/SEC	102
199416	42	239	MUC1/Z	103
199416	42	254	MUC1-IX	106
199417	43	1037	MUC1	3
199417	43	191	MUC1/Y	10
199417	43	278	MUC1-II	11
199417	43	141	MUC1-IV	14
199417	43	436	MUC1-V	16
199417	43	932	MUC1-VI	17
199417	43	206	MUC1/X	20
199417	43	2143	MUC1/SEC	102
199417	43	279	MUC1/Z	103
199417	43	294	MUC1-IX	106
199418	44	1042	MUC1	3
199418	44	196	MUC1/Y	10
199418	44	283	MUC1-II	11
199418	44	146	MUC1-IV	14
199418	44	441	MUC1-V	16
199418	44	937	MUC1-VI	17
199418	44	211	MUC1/X	20
199418	44	2148	MUC1/SEC	102
199418	44	284	MUC1/Z	103
199418	44	299	MUC1-IX	106
199419	45	1056	MUC1	3
199419	45	210	MUC1/Y	10
199419	45	951	MUC1-VI	17
199419	45	298	MUC1/Z	103
199419	45	313	MUC1-IX	106
199420	46	1065	MUC1	3
199420	46	219	MUC1/Y	10
199420	46	3	MUC1-III	12
199420	46	960	MUC1-VI	17
199420	46	2270	MUC1/SEC	102
199420	46	307	MUC1/Z	103
199420	46	322	MUC1-IX	106
199421	47	1091	MUC1	3
199421	47	245	MUC1/Y	10
199421	47	29	MUC1-III	12
199421	47	986	MUC1-VI	17
199421	47	2296	MUC1/SEC	102
199421	47	333	MUC1/Z	103
199421	47	348	MUC1-IX	106
199422	48	1095	MUC1	3
199422	48	249	MUC1/Y	10
199422	48	33	MUC1-III	12

199422	48	990	MUC1-VI	17
199422	48	2300	MUC1/SEC	102
199422	48	337	MUC1/Z	103
199422	48	352	MUC1-IX	106
199423	49	1100	MUC1	3
199423	49	254	MUC1/Y	10
199423	49	38	MUC1-III	12
199423	49	995	MUC1-VI	17
199423	49	2305	MUC1/SEC	102
199423	49	342	MUC1/Z	103
199423	49	357	MUC1-IX	106
199424	50	1112	MUC1	3
199424	50	266	MUC1/Y	10
199424	50	1007	MUC1-VI	17
199424	50	354	MUC1/Z	103
199424	50	369	MUC1-IX	106
199425	51	1115	MUC1	3
199425	51	269	MUC1/Y	10
199425	51	1010	MUC1-VI	17
199425	51	357	MUC1/Z	103
199425	51	372	MUC1-IX	106
199426	52	1168	MUC1	3
199426	52	1063	MUC1-VI	17
199426	52	281	MUC1/X	20
199426	52	2524	MUC1/SEC	102
199426	52	410	MUC1/Z	103
199426	52	425	MUC1-IX	106
199427	53	1217	MUC1	3
199427	53	371	MUC1/Y	10
199427	53	1112	MUC1-VI	17
199427	53	330	MUC1/X	20
199427	53	2573	MUC1/SEC	102
199427	53	459	MUC1/Z	103
199427	53	473	MUC1-IX	106
199428	54	1225	MUC1	3
199428	54	379	MUC1/Y	10
199428	54	1120	MUC1-VI	17
199428	54	338	MUC1/X	20
199428	54	2581	MUC1/SEC	102
199428	54	467	MUC1/Z	103
199428	54	481	MUC1-IX	106
199429	55	1251	MUC1	3
199429	55	405	MUC1/Y	10
199429	55	1146	MUC1-VI	17
199429	55	364	MUC1/X	20
199429	55	493	MUC1/Z	103
199429	55	507	MUC1-IX	106
199430	56	1268	MUC1	3
199430	56	422	MUC1/Y	10
199430	56	69	MUC1-III	12
199430	56	474	MUC1-V	16
199430	56	1163	MUC1-VI	17
199430	56	381	MUC1/X	20

199430	56	510	MUC1/Z	103
199431	57	1371	MUC1	3
199431	57	525	MUC1/Y	10
199431	57	250	MUC1-IV	14
199431	57	577	MUC1-V	16
199431	57	1266	MUC1-VI	17
199431	57	484	MUC1/X	20
199431	57	613	MUC1/Z	103
199431	57	76	MUC1-X	107
199432	58	1397	MUC1	3
199432	58	551	MUC1/Y	10
199432	58	276	MUC1-IV	14
199432	58	603	MUC1-V	16
199432	58	1292	MUC1-VI	17
199432	58	510	MUC1/X	20
199432	58	2977	MUC1/SEC	102
199432	58	639	MUC1/Z	103
199432	58	102	MUC1-X	107
199433	59	1412	MUC1	3
199433	59	566	MUC1/Y	10
199433	59	291	MUC1-IV	14
199433	59	618	MUC1-V	16
199433	59	1307	MUC1-VI	17
199433	59	525	MUC1/X	20
199433	59	2992	MUC1/SEC	102
199433	59	654	MUC1/Z	103
199433	59	117	MUC1-X	107
199434	60	1499	MUC1	3
199434	60	653	MUC1/Y	10
199434	60	425	MUC1-II	11
199434	60	378	MUC1-IV	14
199434	60	704	MUC1-V	16
199434	60	1394	MUC1-VI	17
199434	60	612	MUC1/X	20
199434	60	3078	MUC1/SEC	102
199434	60	741	MUC1/Z	103
199434	60	204	MUC1-X	107
199435	61	1540	MUC1	3
199435	61	694	MUC1/Y	10
199435	61	466	MUC1-II	11
199435	61	419	MUC1-IV	14
199435	61	1435	MUC1-VI	17
199435	61	653	MUC1/X	20
199435	61	782	MUC1/Z	103
199436	62	1582	MUC1	3
199436	62	736	MUC1/Y	10
199436	62	508	MUC1-II	11
199436	62	786	MUC1-V	16
199436	62	1477	MUC1-VI	17
199436	62	695	MUC1/X	20
199436	62	824	MUC1/Z	103
199437	63	1586	MUC1	3
199437	63	740	MUC1/Y	10

199437	63	512	MUC1-II	11
199437	63	790	MUC1-V	16
199437	63	1481	MUC1-VI	17
199437	63	699	MUC1/X	20
199437	63	828	MUC1/Z	103
199438	64	1594	MUC1	3
199438	64	520	MUC1-II	11
199438	64	798	MUC1-V	16
199438	64	1489	MUC1-VI	17
199438	64	707	MUC1/X	20
199438	64	836	MUC1/Z	103
199439	65	1606	MUC1	3
199440	66	1617	MUC1	3
199441	67	1622	MUC1	3
199441	67	1517	MUC1-VI	17
199442	68	1630	MUC1	3
199442	68	833	MUC1-V	16
199442	68	1525	MUC1-VI	17
199443	69	1635	MUC1	3
199443	69	514	MUC1-IV	14
199443	69	1530	MUC1-VI	17
199444	70	141	MUC1/Y	10
199444	70	244	MUC1-IX	106
199445	71	174	MUC1-II	11
199445	71	175	MUC1/Z	103
199446	72	297	MUC1-II	11
199447	73	49	MUC1-III	12
199448	74	3171	MUC1/SEC	102
199448	74	298	MUC1-X	107
199449	75	3279	MUC1/SEC	102
199449	75	407	MUC1-X	107
199450	76	559	MUC1-X	107
199451	77	160	MUC1-IV	14
199452	78	1134	MUC1/SEC	102
199452	78	65	MUC1-VIII	105
199453	79	1269	MUC1/SEC	102
199453	79	202	MUC1-VIII	105
199454	80	455	MUC1-V	16
199455	81	1776	MUC1-VI	17
199456	82	115	MUC1-VII	18
199456	82	58	MUC1/A	100
199456	82	99	MUC1/REP	101
199456	82	116	MUC1-IX	106
199457	83	175	MUC1/X	20
199458	84	1132	MUC1	3
199458	84	286	MUC1/Y	10
199458	84	1027	MUC1-VI	17
199458	84	245	MUC1/X	20
199458	84	2488	MUC1/SEC	102
199458	84	374	MUC1/Z	103
199458	84	389	MUC1-IX	106
199459	85	122	MUC1/D	21
199460	86	85	MUC1/A	100

-92-

199460	86	126	MUC1/REP	101
199460	86	1332	MUC1/SEC	102
199461	87	115	MUC1	3
199461	87	82	MUC1-II	11
199461	87	130	MUC1-VI	17
199461	87	83	MUC1/X	20
199461	87	94	MUC1/A	100
199461	87	135	MUC1/REP	101
199461	87	1341	MUC1/SEC	102
199461	87	83	MUC1/Z	103
199462	88	147	MUC1	3
199462	88	81	MUC1/Y	10
199462	88	114	MUC1-II	11
199462	88	162	MUC1-VI	17
199462	88	183	MUC1-VII	18
199462	88	115	MUC1/X	20
199462	88	126	MUC1/A	100
199462	88	167	MUC1/REP	101
199462	88	1373	MUC1/SEC	102
199462	88	115	MUC1/Z	103
199462	88	154	MUC1/C	104
199462	88	306	MUC1-VIII	105
199462	88	184	MUC1-IX	106
199463	89	188	MUC1	3
199463	89	122	MUC1/Y	10
199463	89	155	MUC1-II	11
199463	89	203	MUC1-VI	17
199463	89	224	MUC1-VII	18
199463	89	156	MUC1/X	20
199463	89	167	MUC1/A	100
199463	89	208	MUC1/REP	101
199463	89	1414	MUC1/SEC	102
199463	89	156	MUC1/Z	103
199463	89	347	MUC1-VIII	105
199463	89	225	MUC1-IX	106
199464	90	207	MUC1	3
199464	90	222	MUC1-VI	17
199464	90	243	MUC1-VII	18
199464	90	186	MUC1/A	100
199464	90	227	MUC1/REP	101
199464	90	1433	MUC1/SEC	102
199464	90	366	MUC1-VIII	105
199465	91	710	MUC1	3
199465	91	109	MUC1-V	16
199465	91	605	MUC1-VI	17
199465	91	1816	MUC1/SEC	102
199466	92	938	MUC1	3
199466	92	42	MUC1-IV	14
199466	92	337	MUC1-V	16
199466	92	833	MUC1-VI	17
199466	92	2044	MUC1/SEC	102
199467	93	987	MUC1	3
199467	93	228	MUC1-II	11

-93-

199467	93	91	MUC1-IV	14
199467	93	386	MUC1-V	16
199467	93	882	MUC1-VI	17
199467	93	2093	MUC1/SEC	102
199467	93	229	MUC1/Z	103
199468	94	1006	MUC1	3
199468	94	160	MUC1/Y	10
199468	94	247	MUC1-II	11
199468	94	110	MUC1-IV	14
199468	94	405	MUC1-V	16
199468	94	901	MUC1-VI	17
199468	94	2112	MUC1/SEC	102
199468	94	248	MUC1/Z	103
199468	94	263	MUC1-IX	106
199469	95	2466	MUC1/SEC	102
199470	96	1281	MUC1	3
199470	96	435	MUC1/Y	10
199470	96	82	MUC1-III	12
199470	96	487	MUC1-V	16
199470	96	1176	MUC1-VI	17
199470	96	394	MUC1/X	20
199470	96	523	MUC1/Z	103
199470	96	538	MUC1-IX	106
199471	97	3292	MUC1/SEC	102
199471	97	420	MUC1-X	107

What is claimed is:

5 1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding mucin 1, transmembrane, wherein said compound specifically hybridizes with said nucleic acid molecule encoding mucin 1, transmembrane and inhibits the expression of mucin 1, transmembrane.

10 2. The compound of claim 1 which is an antisense oligonucleotide.

3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 15 43, 44, 45, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 66, 67, 68, 69, 72, 74, 75, 76, 78, 79, 80, 81, 88, 89, 90, 91, 93, 94, 96, 97, 98 or 99.

4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside 20 linkage.

5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

25 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. The compound of claim 8 wherein the modified 30 nucleobase is a 5-methylcytosine.

10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of 35 an active site on a nucleic acid molecule encoding mucin 1, transmembrane.

12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

-95-

13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.

5 15. A method of inhibiting the expression of mucin 1, transmembrane in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of mucin 1, transmembrane is inhibited.

10 16. A method of treating an animal having a disease or condition associated with mucin 1, transmembrane comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of mucin 1, transmembrane is inhibited.

15 17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

18. The method of claim 16 wherein the disease or disorder is an inflammatory disorder.

20 19. The compound of claim 1 targeted to a nucleic acid molecule encoding mucin 1, transmembrane, wherein said compound specifically hybridizes with and differentially inhibits the expression of one of the variants of mucin 1, transmembrane relative to the remaining variants of of mucin 1, transmembrane.

25 20. The compound of claim 19 targeted to a nucleic acid molecule encoding of mucin 1, transmembrane, wherein said compound hybridizes with and specifically inhibits the expression of a variant of of mucin 1, transmembrane, wherein said variant is selected from the group consisting of MUC1, MUC1/Y, MUC1/X, MUC1/D, MUC1/A, MUC1/REP, MUC1/SEC, MUC1/Z, MUC1/C, MUC1-II, MUC1-III, MUC1-IV, MUC1-V, MUC1-VI, MUC1-VII, 30 MUC1-VIII, MUC1-IX and MUC1-X.

SEQUENCE LISTING

<110> Kenneth W. Dobie
 Susan J. Myers
 Isis Pharmaceuticals, Inc.

<120> ANTISENSE MODULATION OF MUCIN 1, TRANSMEMBRANE EXPRESSION

<130> RTSP-0442

<150> 10/029,517
 <151> 2001-12-20

<160> 107

<210> 1
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1
 tccgtcatcg ctcctcaggg 20

<210> 2
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2
 atgcattctg cccccaagga 20

<210> 3
 <211> 1721
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (58)...(1605)

<400> 3
 gaattccctg gctgcttgaa tctgtttotgc cccctcccca cccatttcac caccacc 57

atg aca cag ggc acc cag tct cct ttc ttc ctg ctg ctg ctc ctc aca 105

Met	Thr	Pro	Gly	Thr	Gln	Ser	Pro	Phe	Phe	Leu	Leu	Leu	Leu	Leu	Thr		
1				5					10						15		
gtg	ctt	aca	gtt	gtt	aca	ggg	tct	ggg	cat	gca	agc	tct	acc	cca	ggg	153	
Val	Leu	Thr	Val	Val	Thr	Gly	Ser	Gly	His	Ala	Ser	Ser	Thr	Pro	Gly		
			20					25					30				
gga	gaa	aag	gag	act	tcg	gct	acc	cag	aga	agt	tca	gtg	ccc	agc	tct	201	
Gly	Glu	Lys	Glu	Thr	Ser	Ala	Thr	Gln	Arg	Ser	Ser	Val	Pro	Ser	Ser		
		35					40					45					
act	gag	aag	aat	gct	gtg	agt	atg	acc	agc	agc	gta	ctc	tcc	agc	cac	249	
Thr	Glu	Lys	Asn	Ala	Val	Ser	Met	Thr	Ser	Ser	Val	Leu	Ser	Ser	His		
	50					55					60						
agc	ccc	ggg	tca	ggc	tcc	tcc	acc	act	cag	gga	cag	gat	gtc	act	ctg	297	
Ser	Pro	Gly	Ser	Gly	Ser	Ser	Thr	Thr	Gln	Gly	Gln	Asp	Val	Thr	Leu		
65					70				75						80		
gcc	ccg	gcc	acg	gaa	cca	gct	tca	ggg	tca	gct	gcc	acc	tgg	gga	cag	345	
Ala	Pro	Ala	Thr	Glu	Pro	Ala	Ser	Gly	Ser	Ala	Ala	Thr	Trp	Gly	Gln		
			85					90						95			
gat	gtc	acc	tcg	gtc	cca	gtc	acc	agg	cca	gcc	ctg	ggc	tcc	acc	acc	393	
Asp	Val	Thr	Ser	Val	Pro	Val	Thr	Arg	Pro	Ala	Leu	Gly	Ser	Thr	Thr		
			100					105					110				
ccg	cca	gcc	cac	gat	gtc	acc	tca	gcc	ccg	gac	aac	aag	cca	gcc	ccg	441	
Pro	Pro	Ala	His	Asp	Val	Thr	Ser	Ala	Pro	Asp	Asn	Lys	Pro	Ala	Pro		
		115					120					125					
ggc	tcc	acc	gcc	ccc	cca	gcc	cac	ggg	gtc	acc	tcg	gcc	ccg	gac	acc	489	
Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Thr		
	130					135					140						
agg	ccg	ccc	ccg	ggc	tcc	acc	gcc	ccc	cca	gcc	cac	ggg	gtc	acc	tcg	537	
Arg	Pro	Pro	Pro	Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser		
145					150					155					160		
gcc	ccg	gac	acc	agg	ccg	ccc	ccg	ggc	tcc	acc	gcg	ccc	gca	gcc	cac	585	
Ala	Pro	Asp	Thr	Arg	Pro	Pro	Pro	Gly	Ser	Thr	Ala	Pro	Ala	Ala	His		
			165					170					175				
ggg	gtc	acc	tcg	gcc	ccg	gac	acc	agg	ccg	gcc	ccg	ggc	tcc	acc	gcc	633	
Gly	Val	Thr	Ser	Ala	Pro	Asp	Thr	Arg	Pro	Ala	Pro	Gly	Ser	Thr	Ala		
			180					185					190				
ccc	cca	gcc	cat	ggg	gtc	acc	tcg	gcc	ccg	gac	aac	agg	ccc	gcc	ttg	681	
Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Asn	Arg	Pro	Ala	Leu		
		195					200					205					
gcg	tcc	acc	gcc	cct	cca	gtc	cac	aat	gtc	acc	tcg	gcc	tca	ggc	tct	729	
Ala	Ser	Thr	Ala	Pro	Pro	Val	His	Asn	Val	Thr	Ser	Ala	Ser	Gly	Ser		
	210					215					220						
gca	tca	ggc	tca	gct	tct	act	ctg	gtg	cac	aac	ggc	acc	tct	gcc	agg	777	
Ala	Ser	Gly	Ser	Ala	Ser	Thr	Leu	Val	His	Asn	Gly	Thr	Ser	Ala	Arg		
225					230					235					240		

gct acc aca acc cca gcc agc aag agc act cca ttc tca att ccc agc	825
Ala Thr Thr Thr Pro Ala Ser Lys Ser Thr Pro Phe Ser Ile Pro Ser	
245 250 255	
cac cac tct gat act cct acc acc ctt gcc agc cat agc acc aag act	873
His His Ser Asp Thr Pro Thr Thr Leu Ala Ser His Ser Thr Lys Thr	
260 265 270	
gat gcc agt agc act cac cat agc acg gta cct cct ctc acc tcc tcc	921
Asp Ala Ser Ser Thr His His Ser Thr Val Pro Pro Leu Thr Ser Ser	
275 280 285	
aat cac agc act tct ccc cag ttg tct act ggg gtc tct ttc ttt ttc	969
Asn His Ser Thr Ser Pro Gln Leu Ser Thr Gly Val Ser Phe Phe Phe	
290 295 300	
ctg tct ttt cac att tca aac ctc cag ttt aat tcc tct ctg gaa gat	1017
Leu Ser Phe His Ile Ser Asn Leu Gln Phe Asn Ser Ser Leu Glu Asp	
305 310 315 320	
ccc agc acc gac tac tac caa gag ctg cag aga gac att tct gaa atg	1065
Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln Arg Asp Ile Ser Glu Met	
325 330 335	
ttt ttg cag att tat aaa caa ggg ggt ttt ctg ggc ctc tcc aat att	1113
Phe Leu Gln Ile Tyr Lys Gln Gly Gly Phe Leu Gly Leu Ser Asn Ile	
340 345 350	
aag ttc agg cca gga tct gtg gtg gta caa ttg act ctg gcc ttc cga	1161
Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu Ala Phe Arg	
355 360 365	
gaa ggt acc atc aat gtc cac gac gtg gag aca cag ttc aat cag tat	1209
Glu Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr	
370 375 380	
aaa acg gaa gca gcc tct cga tat aac ctg acg atc tca gac gtc agc	1257
Lys Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser	
385 390 395 400	
gtg agt gat gtg cca ttt cct ttc tct gcc cag tct ggg gct ggg gtg	1305
Val Ser Asp Val Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val	
405 410 415	
cca ggc tgg ggc atc gcg ctg ctg gtg ctg gtc tgt gtt ctg gtt gcg	1353
Pro Gly Trp Gly Ile Ala Leu Leu Val Leu Val Cys Val Leu Val Ala	
420 425 430	
ctg gcc att gtc tat ctc att gcc ttg gct gtc tgt cag tgc cgc cga	1401
Leu Ala Ile Val Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg	
435 440 445	
aag aac tac ggg cag ctg gac atc ttt cca gcc cgg gat acc tac cat	1449
Lys Asn Tyr Gly Gln Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His	
450 455 460	
cct atg agc gag tac ccc acc tac cac acc cat ggg cgc tat gtg ccc	1497
Pro Met Ser Glu Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro	
465 470 475 480	

cct agc agt acc gat cgt agc ccc tat gag aag gtt tct gca ggt aat 1545
 Pro Ser Ser Thr Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn
 485 490 495

ggt ggc agc agc ctc tct tac aca aac cca gca gtg gca gcc act tct 1593
 Gly Gly Ser Ser Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser
 500 505 510

gcc aac ttg tag gggcacgtcg ccctctgagc tgagtggcca gccagtgcc 1645
 Ala Asn Leu
 515

ttccactcca ctcagggctc tctgggccag tctctctggg agccccacc acaacacttc 1705
 ccaggcatgg aattcc 1721

<210> 4
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> PCR Primer

<400> 4
 tgactctggc cttccgagaa 20

<210> 5
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5
 gctgcttccg ttttatactg attg 24

<210> 6
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>

<223> PCR Probe

<400> 6
 taccatcaat gtccacgacg tggagaca 28

<210> 7
 <211> 19
 <212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 7

gaaggtgaag gtcggagtc

19

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8

gaagatggtg atgggatttc

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 9

caagcttccc gttctcagcc

20

<210> 10

<211> 759

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(759)

<400> 10

atg aca ccg ggc acc cag tct cct ttc ttc ctg ctg ctg ctc ctc aca
Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr
1 5 10 15

48

gtg ctt aca ggt tct ggt cat gca agc tct acc cca ggt gga gaa aag
Val Leu Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly Gly Glu Lys
20 25 30

96

gag act tcg gct acc cag aga agt tca gtg ccc agc tct act gag aag
Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser Thr Glu Lys
35 40 45

144

aat gct ttt aat tcc tct ctg gaa gat ccc agc acc gac tac tac caa	192
Asn Ala Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln	
50 55 60	
 gag ctg cag aga gac att tct gaa atg ttt ttg cag att tat aaa caa	240
Glu Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln	
65 70 75 80	
 ggg ggt ttt ctg ggc ctc tcc aat att aag ttc agg cca gga tct gtg	288
Gly Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val	
85 90 95	
 gtg gta caa ttg act ctg gcc ttc cga gaa ggt acc atc aat gtc cac	336
Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His	
100 105 110	
 gac atg gag aca cag ttc aat cag tat aaa acg gaa gca gcc tct cga	384
Asp Met Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg	
115 120 125	
 tat aac ctg acg atc tca gac gtc agc gtg agt gat gtg cca ttt cct	432
Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro	
130 135 140	
 ttc tct gcc cag tct ggg gct ggg gtg cca ggc tgg ggc atc gcg ctg	480
Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala Leu	
145 150 155 160	
 ctg gtg ctg gtc tgt gtt ctg gtt gcg ctg gcc att gtc tat ctc att	528
Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu Ile	
165 170 175	
 gcc ttg gct gtc tgt cag tgc cgc cga aag aac tac ggg cag ctg gac	576
Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu Asp	
180 185 190	
 atc ttt cca gcc cgg gat acc tac cat cct atg agc gag tac ccc acc	624
Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro Thr	
195 200 205	
 tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc gat cgt agc	672
Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg Ser	
210 215 220	
 ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc ctc tct tac	720
Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr	
225 230 235 240	
 aca aac cca gca gtg gca gcc act tct gcc aac ttg tag	759
Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu	
245 250	

<210> 11

<211> 543

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (25)...(531)

<400> 11

```

ctccccaccc atttcaccac cacc atg aca ccg ggc acc cag tct cct ttc      51
                               Met Thr Pro Gly Thr Gln Ser Pro Phe
                               1             5

ttc ctg ctg ctg ctc ctc aca gtg ctt aca gtt gtt aca ggt tct ggt      99
Phe Leu Leu Leu Leu Leu Thr Val Leu Thr Val Val Thr Gly Ser Gly
 10             15             20             25

cat gca agc tct acc cca ggt gga gaa aag gag act tcg gct acc cag      147
His Ala Ser Ser Thr Pro Gly Gly Glu Lys Glu Thr Ser Ala Thr Gln
             30             35             40

aga agt tca gtg ccc agc tct act gag aag aat gct ttg tct act ggg      195
Arg Ser Ser Val Pro Ser Ser Thr Glu Lys Asn Ala Leu Ser Thr Gly
             45             50             55

gtc tct ttc ttt ttc ctg tct ttt cac att tca aac ctc cag ttt aat      243
Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu Gln Phe Asn
             60             65             70

tcc tct ctg gaa gat ccc agc acc gac tac tac caa gag ctg cag aga      291
Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln Arg
             75             80             85

gac att tct gaa atg gct gtc tgt cag tgc cgc cga aag aac tac ggg      339
Asp Ile Ser Glu Met Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly
             90             95             100             105

ctg ctg gac atc ttt cca gcc cgg gat acc tac cat cct atg agc gag      387
Leu Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu
             110             115             120

tac ccc acc tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc      435
Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr
             125             130             135

gat cgt agc ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc      483
Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser
             140             145             150

ctc tct tac aca aac cca gca gtg gca gcc act tct gcc aac ttg tag      531
Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu
             155             160             165

gggcacgtcg cc      543

```

<210> 12

<211> 122

<212> DNA

<213> Homo sapiens

<220>

<221> exon:exon junction

<222> (58)...(59)

<223> exon 4:exon 6

<400> 12

atgtttttgc	agatttataa	acaagggggg	tttctggggc	tctccaatat	taagttcagt	60
gagtgatgtg	ccatttcctt	tctctgcccc	gtctggggct	ggggtgccag	gctggggcat	120
cg						122

<210> 13

<211> 000

<212> DNA

<213> Homo sapiens

<220>

<400> 13

000

<210> 14

<211> 577

<212> DNA

<213> Homo sapiens

<220>

<221> exon:exon junction

<222> (169)...(170)

<223> exon 3c:exon 6b

<400> 14

cggtgtcgga	ctgctcacct	cctccaatca	cagcacttct	ccccagttgt	ctactggggg	60
ctctttcttt	ttcctgtctt	ttcacatttc	aaacctocag	tttaattcct	ctctggaaga	120
tcccagcacc	gactactacc	aagagctgca	gagagacatt	tctgaaatgt	ctggggctgg	180
ggtgccaggc	tggggcatcg	cgtgtctggt	gctgggtctgt	gttctggttg	cgctggccat	240
tgtctatctc	attgccttgg	ctgtctgtca	gtgccgccga	aagaactacg	ggcagctgga	300
catctttcca	gcccgggata	cctaccatcc	tatgagcgag	tacccacact	accacaccca	360
tgggcgctat	gtgcccccta	gcagtaccga	tcgtagcccc	tatgagaagg	tttctgcagg	420
taatggtggc	agcagcctct	cttacacaaa	cccagcagtg	gcagccactt	cttgcaactt	480
gtagggggca	gtcgcccgct	gagctgagta	gccagccagt	gccattccac	tccactcagg	540
ttcttcaggg	ccagagcccc	tgcaccctgt	ttgggct			577

<210> 15

<211> 000

<212> DNA

<213> Homo sapiens

<220>

<400> 15

000

<210> 16

<211> 981

<212> DNA

<213> Homo sapiens

<220>

<221> exon:exon junction

<222> (464)...(465)

<223> exon 3b:exon 4

<400> 16

```

gggacaccag gccggccccg ggtccaccg cccccccagc ccatgggtgtc acctcggccc      60
cggacaacag gcccgcccttg ggtccaccg cccctccagt ccacaatgtc acctcggcct      120
caggtctctgc atcaggtctca gcttctactc tgggtgcacaa cagcacctct gccagggcta      180
ccacaacccc agccagcaag agcactccat tctcaattcc cagccaccac tctgatactc      240
ctaccacoot tgccagccat agcaccaaga ctgatgccag tagcaactac catagcacgg      300
tacctcctct cacctcctcc aatcacagca ctctctccca gttgtctact ggggtctctt      360
tcttttttct gtctttttcac atttcaaacc tccagtttaa ttctctctct gaagatccca      420
gcaccgacta ctaccaagag ctgcagagag acattttctga aatgtgagtg atgtgccatt      480
tccttttctct gccaggtctg gggctggggg gccaggctgg ggcacgcgcg tgctgggtgt      540
gggtctgtgtt ctggttgccg tggccattgt ctatctcatt gccttggtct tctgtcagtg      600
ccgcccgaag aactacgggc agctggacat ctttccagcc cgggatacct accatcctat      660
gagcgagtac cccacctacc aaccctatgg ogetatgtgc cccctagcag taccgatcgt      720
agcccctatg agacaggttt ctgcaggtaa tgggtggcagc agctctctta cacaaccag      780
cagtggcagc cacttctgcc aacttgtagg ggcacgttgc cgctgacctg agtggccagc      840
cagtgccatt ccaattccac tcagggttct tcaggggcca gagccctgca ccctgtttgg      900
cctggtgagc tggacttcaa ggtgggctgt cacagcctct tcaaaggccc acaattcttc      960
gacatcctca ggtgtggaag c                                     981

```

<210> 17

<211> 1804

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (73)...(1500)

<400> 17

```

cgctccacct ctcaagcagc cagcgcctgc ctgaatctgt totgccccct cccacccat      60
ttcaccacca cc atg aca ccg ggc acc cag tot cct ttc ttc ctg ctg ctg      111
      Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu
              1             5             10

ctc ctc aca gtg ctt aca gtt gtt aca ggt tot ggt cat gca agc tct      159
Leu Leu Thr Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser
      15             20             25

acc cca ggt gga gaa aag gag act tcg gct acc cag aga agt tca gtg      207
Thr Pro Gly Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val
      30             35             40             45

ccc agc tct act gag aag aat gct gtg agt atg acc agc agc gta ctc      255
Pro Ser Ser Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu
              50             55             60

tcc agc cac agc ccc ggt tca ggc tcc tcc acc act cag gga cag gat      303
Ser Ser His Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp
              65             70             75

```

gtc act ctg gcc ccg gcc acg gaa cca gct tca ggt tca gct gcc acc	351
Val Thr Leu Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr	
80 85 90	
tggt gga cag gat gtc acc tcg gtc cca gtc acc agg cca gcc ctg ggc	399
Trp Gly Gln Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly	
95 100 105	
tcc acc acc ccg cca gcc cac gat gtc acc tca gcc ccg gac aac aag	447
Ser Thr Thr Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys	
110 115 120 125	
cca gcc ccg ggc tcc acc gcc ccc cca gcc cac ggt gtc acc tcg gcc	495
Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala	
130 135 140	
ccg gac acc agg ccg gcc ccg ggc tcc acc gcc ccc cca gcc cat ggt	543
Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly	
145 150 155	
gtc acc tcg gcc ccg gac aac agg ccc gcc ttg ggc tcc acc gcc cct	591
Val Thr Ser Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala Pro	
160 165 170	
cca gtc cac aat gtc acc tcg gcc tca ggc tct gca tca ggc tca gct	639
Pro Val His Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala	
175 180 185	
tct act ctg gtg cac aac ggc acc tct gcc agg gct acc aca acc cca	687
Ser Thr Leu Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro	
190 195 200 205	
gcc agc aag agc act cca ttc tca att ccc agc cac cac tct gat act	735
Ala Ser Lys Ser Thr Pro Phe Ser Ile Pro Ser His His Ser Asp Thr	
210 215 220	
cct acc acc ctt gcc agc cat agc acc aag act gat gcc agt agc act	783
Pro Thr Thr Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser Thr	
225 230 235	
cac cat agc acg gta cct cct ctc acc tcc tcc aat cac agc act tct	831
His His Ser Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr Ser	
240 245 250	
ccc cag ttg tct act ggg gtc tct ttc ttt ttc ctg tct ttt cac att	879
Pro Gln Leu Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile	
255 260 265	
tca aac ctc cag ttt aat tcc tct ctg gaa gat ccc agc acc gac tac	927
Ser Asn Leu Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr	
270 275 280 285	
tac caa gag ctg cag aga gac att tct gaa atg ttt ttg cag att tat	975
Tyr Gln Glu Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr	
290 295 300	
aaa caa ggg ggt ttt ctg ggc ctc tcc aat att aag ttc agg cca gga	1023
Lys Gln Gly Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly	

11

305	310	315	
tct gtg gtg gta caa ttg act ctg gcc ttc cga gaa ggt acc atc aat			1071
Ser Val Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn			
320	325	330	
gtc cac gac gtg gag aca cag ttc aat cag tat aaa acg gaa gca gcc			1119
Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala			
335	340	345	
tct cga tat aac ctg acg atc tca gac gtc agc gtg agt gat gtg cca			1167
Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro			
350	355	360	365
ttt cct ttc tct gcc cag tct ggg gct ggg gtg cca ggc tgg ggc atc			1215
Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile			
370	375	380	
gcg ctg ctg gtg ctg gtc tgt gtt ctg gtt gcg ctg gcc att gtc tat			1263
Ala Leu Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr			
385	390	395	
ctc att gcc ttg gct gtc tgt cag tgc cgc cga aag aac tac ggg cag			1311
Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln			
400	405	410	
ctg gac atc ttt cca gcc cgg gat acc tac cat cct atg agc gag tac			1359
Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr			
415	420	425	
ccc acc tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc gat			1407
Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp			
430	435	440	445
cgt agc ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc ctc			1455
Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu			
450	455	460	
tct tac aca aac cca gca gtg gca gcc act tct gcc aac ttg tag			1500
Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu			
465	470	475	
gggcaogtcg cccgctgagc tgagtggcca gccagtgccca ttccactcca ctcaggttct			1560
tcagggccag agcccctgca ccctgttttg gctggtgagc tgggagttca ggtgggctgc			1620
tcacaccgtc cttcagaggc cccaccaatt tctcggacac ttctcagtgt gtggaagctc			1680
atgtgggccc ctgaggtc tgcctgggaa gtgttggtgt gggggctccc aggaggactg			1740
gccagagag ccctgagata ggggggatcc tgaactggac tgaataaaac gtggtctccc			1800
actg			1804
<210> 18			
<211> 572			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> CDS			
<222> (67)...(572)			

<400> 18
 acctctcaag cagccagcgc ctgcctgaat ctgtttctgcc ccctcccccac ccatttcacc 60
 accacc atg aca ccg ggc acc cag tct cct ttc ttc ctg ctg ctg ctc 108
 Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu
 1 5 10

ctc aca gtg ctt aca gct acc aca gcc cct aaa ccc gca aca gtt gtt 156
 Leu Thr Val Leu Thr Ala Thr Thr Ala Pro Lys Pro Ala Thr Val Val
 15 20 25 30

acg ggt tct ggt cat gca agc tct acc cca ggt gga gaa aag gag act 204
 Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly Gly Glu Lys Glu Thr
 35 40 45

tcg gct acc cag aga agt tca gtg ccc agc tct act gag aag aat gct 252
 Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser Thr Glu Lys Asn Ala
 50 55 60

gtg agt atg acc agc agc gta ctc tcc agc cac agc ccc ggt tca ggc 300
 Val Ser Met Thr Ser Ser Val Leu Ser Ser His Ser Pro Gly Ser Gly
 65 70 75

tcc tcc acc act cag gga cag gat gtc act ctg gcc ccg gcc acg gaa 348
 Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu Ala Pro Ala Thr Glu
 80 85 90

cca gct tca ggt tca gct gcc acc tgg gga cag gat gtc acc tcg gtc 396
 Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln Asp Val Thr Ser Val
 95 100 105 110

cca gtc acc agg cca gcc ctg ggc tcc acc acc ccg cca gcc cac gat 444
 Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr Pro Pro Ala His Asp
 115 120 125

gtc acc tca gcc ccg gac aac aag cca gcc ccg ggc tcc acc gcc ccc 492
 Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro Gly Ser Thr Ala Pro
 130 135 140

caa gcc cac ggt gtc acc tcg gcc ccg gac acc agg ccg gcc ccg ggc 540
 Gln Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly
 145 150 155

tcc acc gcc ccc caa gcc cac ggt gtc acc tc 572
 Ser Thr Ala Pro Gln Ala His Gly Val Thr
 160 165

<210> 19
 <211> 8186
 <212> DNA
 <213> Homo sapiens

<220>

<221> unsure
 <222> 6899
 <223> unknown

<221> unsure

<222> 7155
<223> unknown

<221> unsure
<222> 7184
<223> unknown

<221> unsure
<222> 7957
<223> unknown

<221> intron
<222> (2997)...(3498)
<223> intron 1

<221> intron:exon junction
<222> (3498)...(3499)
<223> intron 1:exon 2

<221> exon
<222> (3508)...(3599)
<223> exon 2d

<221> exon:intron junction
<222> (3982)...(3983)
<223> exon 2a:intron 2a

<221> intron:exon junction
<222> (4205)...(4206)
<223> intron 2c:exon 3c

<221> intron:exon junction
<222> (4259)...(4260)
<223> intron 2d:exon 3d

<221> exon
<222> (4260)...(4328)
<223> exon 3d

<221> intron:exon junction
<222> (4632)...(4633)
<223> intron 3:exon 4

<221> exon
<222> (4914)...(5035)
<223> exon 5

<221> intron
<222> (5266)...(6293)
<223> intron 6

<400> 19	
gaattcagaa ttttagaccc tttggccttg ggggccatcc tggagaccct gaggtctaag	60
ctacagcccc tcagccaacc acagaccctt ctctggctcc caaaaggagt tcagtcccag	120
agggtggtca cccacccttc agggatgaga agttttcaag gggattact caggcactaa	180
ccccaggaaa gatgacagca cattgccata aagttttggt tgttttctaa gccagtgcga	240
ctgcttatatt tagggatttt ccgggatagg gtggggaaagt ggaaggaatc ggcgagtaga	300
agagaaaagcc tgggagggtg gaagttaggg atctagggga agtttggtctg atttggggat	360
gcgggtgggg gaggtgctgg atggagttaa gtgaaggata ggggtgcctga gggaggatgc	420

ccgaagtcct	cccagaccca	cttactcagc	gtggcagcgg	cgacactcca	gtctatcaaa	480
gatccgcggg	gatggagagc	caggaggcgg	gggctgcccc	tgaggtagcg	gggaggccgg	540
ggggccgggg	ggcggacggg	acgagtgcac	tattggcggg	ggaaaaaaca	acactgcacc	600
gcgtcccgtc	cctcccgccc	gcccgggccc	ggatcccgct	ccccaccgcc	tgaagccggc	660
ccgaccggga	acccgggccc	ctggggaggt	gggttcacct	tggaggccag	agagacttgg	720
cgcccggaa	caaagggaat	ggcaaggggg	aggggggagg	gagaacggga	gtttgoggag	780
tccagaaggc	cgttttcga	cgcccggggc	ttgcgcgcgc	ttgctcttta	agtactcaga	840
ctgcgcggcg	cgagccgtcc	gcatggtgac	gcgtgtccca	gcaaccgaac	tgaatggctg	900
ttgcttgga	atgcggggag	ttgaggtttg	gggcggccca	cctagctact	cgtgttttct	960
ccggcctgcg	agttgggggg	ctcccgccct	cccgcccgcc	tcctggggcg	gctgacgtca	1020
gatgtcccca	ccccgcccag	cgcttgcgcc	aagggtctcg	ccgcacacaa	agctcggcct	1080
cgggcgccgg	cgcgcgggcg	agagcggtgg	tctctcgcc	gctgatctga	tgcgctccaa	1140
tcccgctgct	cgccgaagtg	tttttaaagt	gttctttcca	acctgtgtct	ttggggctga	1200
gaactgtttt	ctgaatacag	gcggaactgc	ttccgtcgcc	ctagaggcac	gctgcgactg	1260
cgggaccocaa	gttccacgtg	ctgcgcggcg	ctgggatagc	ttcctccccc	cgtgcactgc	1320
tgccgcacac	acctcttggc	tgtcgcgcac	tacgcacctc	acgtgtgctt	ttgcccccg	1380
ctacgtgctt	acctgtcccc	aataccactc	gtctcccca	aggatagttc	tgtgtccgta	1440
aatcccatte	tgtaccccca	cctactctct	gccccccccc	tttttgtttt	gagacggagc	1500
tttgctctgt	cgcccaggct	ggagtgcac	ggcgcgatct	cggtcactg	caacctccgc	1560
ctcccggtt	caagcgattc	tcctgcctca	gcctcctgag	tagctggggg	tacagcgccc	1620
gccaccacgc	tcggctaatt	tttgtagttt	ttagtagaga	cgaggtttca	ccatcttggc	1680
caggctgggt	ttgaacccct	gaccttgtga	tcactcgcc	tcggccttcc	aaagtgttgg	1740
gattacgggg	gtgacgaccg	tgccacgcac	ctgcctctta	agtacataac	ggcccacaca	1800
gaacgtgtcc	aactcccccg	cccacgttcc	aacgtcctct	cccacatacc	tcgggtgcccc	1860
ttccacatac	ctcaggaccc	caccgcctta	gctccatttc	ctccagacgc	caccaccacg	1920
cgtcccggag	tgccccctcc	taaagctccc	agccgtccac	catgctgtgc	gttcctccct	1980
ccctggccac	ggcagtgacc	cttctctccc	gggccctgct	tcctctctgc	gggctctgct	2040
gcctcactta	ggcagcgctg	cccttactcc	tctccgcccc	gtccgagcgg	cccctcagct	2100
tcggcgccca	gccccgcaag	gctcccgggt	accactagag	ggcgggagga	gctcctggcc	2160
agtggtggag	agtggaagg	aaggacccta	gggttcacgc	gagcccagg	ttactccctt	2220
aagtggaaat	ttcttcccc	actcctcctt	ggctttctcc	aaggaggga	cccaggctgc	2280
tggaaagtcc	ggctgggggg	gggactgtgg	gttcagggga	gaacgggggt	tggaaacggga	2340
caggagcgcg	ttagaagggt	ggggctattc	cggaagtgg	tggggggagg	gagcccaaaa	2400
ctagcaccta	gtccactcat	tatccagccc	tcttatttct	cggccgctct	gcttcagtgg	2460
acccggggag	ggcggggaag	tggagtggga	gacctagggg	tgggcttccc	gacottgctg	2520
tacaggacct	gcacctagct	ggctttgttc	cccatcccca	cgttagtgtg	tgccctgagg	2580
ctaaaactag	agcccagggg	ccccaaagtt	cagactgccc	ctccccctc	ccccggagcc	2640
agggagtggg	tgggtgaaag	gggaggccag	ctggagaaca	aacgggtagt	caggggggtg	2700
agcgattaga	gccctgttac	cctaccaggg	aatgggtggg	gaggaggagg	aagaggtagg	2760
aggtagggga	gggggcgggg	ttttgtcacc	tgtcacctgc	tcgctgtgcc	tagggcgggc	2820
gggcggggag	tggggggacc	ggtataaagc	ggtaggcgcc	tgtgcccgtc	ccacctctca	2880
agcagccagc	gcctgcctga	atctgttctg	ccccctcccc	accatttca	ccaccacct	2940
gacaccgggc	accagctctc	ctttcttctc	gctgctgctc	ctcacagtgc	ttacagggtga	3000
ggggcacgag	gtggggagtg	ggctgcccgt	cttaggtggg	cttcgtgggc	tttctgtggg	3060
ttttgctccc	tggcagatgg	caccatgaag	ttaaagtaag	aattgcagac	agaggctgcc	3120
ctgtctgtgc	cagaaggagg	gagaggctaa	ggacaggctg	agaagagttg	cccccaacc	3180
tgagagtggg	taccaggggc	aagcaaagt	cctgtagaga	agtctagggg	gaagagagta	3240
gggagaggga	aggcttaaga	ggggaagaaa	tgcaggggcc	atgagccaag	gcctatgggc	3300
agagagaagg	aggctgctgc	agggaaggag	gcttcccaac	caggggttac	tgaggctgcc	3360
cactccccag	tcctcctggg	attattttct	tgggtggccag	agcttatatt	ttcttcttgc	3420
tcttattttt	ccttcataaa	gacccaaccc	tatgacttta	acttcttaca	gctaccacag	3480
cccctaaacc	cgcaacagtt	gttacaggtt	ctggtcatgc	aagctctacc	ccagggtggg	3540
aaaaggagac	ttcggctacc	cagagaagtt	cagtgccag	ctctactgag	aagaatgctg	3600
tgagtatgac	cagcagcgta	ctctccagcc	acagccccgg	ttcagggtcc	tccaccactc	3660
agggacagga	tgtcactctg	gccccggcca	cggaaccagc	ttcagggtca	gctgcccact	3720
ggggacagga	tgtcacctcg	gtcccagtc	ccaggccagc	cctgggctcc	accacccccg	3780
cagcccacga	tgtcacctca	gccccggaca	acaagccagc	cccgggctcc	accgcccccc	3840
cagcccacgg	tgtcacctcg	gccccggaca	ccaggccggc	cccgggctcc	accgcccccc	3900
cagcccacgg	tgtcacctcg	gccccggaca	acaggcccg	cttgggctcc	accgcccccc	3960

cagtcacaaa	tgctacactcg	gcctcaggct	ctgcactcagg	ctcagcttct	actctgggtgc	4020
acaaocggcac	ctctgccagg	getaccacaa	ccccagccag	caagagcact	ccattctcaa	4080
ttcccagcca	ccactctgat	actcctacca	cccttgccag	ccatagcacc	aagactgatg	4140
ccagtagcac	tcaccatagc	acgggtacctc	ctctcaacctc	ctccaatcac	agcactttctc	4200
cccagttgtc	tactgggggtc	tctttctttt	tctgtgtttt	tcacatttca	aacctccagt	4260
tttaattctc	tctggaagat	cccagcacccg	actactacca	agagctgcag	agagacattt	4320
ctgaaatggg	gagtatcgcc	ctttccttcc	ccatgctccc	ctgaagcagc	catcagaact	4380
gtccacaccc	tttgcatcaa	gcccaggtcc	tttccctctc	accccagttt	ttgcagattt	4440
ataaacaagg	gggttttctg	ggcctctcca	atattaagtt	caggtacagt	tctgggtgtg	4500
gacccagtg	gggtgttggg	gggttgggtg	gtggtcatga	ccgtaggagg	gactgggtgca	4560
cttaaggttg	ggggaagagt	gctgagccag	agctgggacc	cgtggctgaa	gtgccattt	4620
ccctgtgacc	aggccaggat	ctgtgggtgt	acaattgact	ctggccttcc	gagaagggtac	4680
catcaatgtc	cacgacgtgg	agacacagtt	caatcagtat	aaaacggaag	cagcctctcg	4740
atataacctg	acgatctcag	acgtcagcgg	tgaggctact	tccctggctg	cagccagcac	4800
catgccgggg	cccctctcct	tccagtgtct	gggtccccgc	tctttcctta	gtgctggcag	4860
cgggaggggc	gcctcctctg	ggagactgcc	ctgaccactg	cttttctttt	tagtgagtga	4920
tgtgccattt	cctttctctg	cccagctctg	ggctgggggtg	ccaggctggg	gcatcgogct	4980
gctgggtgtg	gtctgtgttc	tgggtgctgt	ggccattgtc	tatctcattg	ccttgggtgag	5040
tgagtcacct	ggccctgata	agagccccc	ggtagaaggc	actccatggc	ctgccataac	5100
ctcctatctc	cccaggctgt	ctgtcagtgc	cgccgaaaga	actacgggca	gctggacatc	5160
tttccagccc	gggataccta	ccatcctatg	agcaggtacc	ccacctacca	caccatggg	5220
cgctatgtgc	cccctagcag	taccgatcgt	agccctatg	agaagggtgag	attggcccca	5280
caggccaggg	gaagcagagg	gtttggctgg	gcaaggattc	tgaagggggg	acttggaaaa	5340
cccaaagagc	ttggaagagg	tgagaagtgg	cgtgaagtga	gcaggggagg	gcctggcaag	5400
gatgaggggc	agaggtcaga	ggagtttttg	gggacaggcc	tgggaggaga	ctatgggaaga	5460
aaggggcctc	aagagggagt	ggccccactg	ccagaattcc	taaaaagatc	attggccgtc	5520
cacattcatg	ctggctggcg	ctggctgaac	tgggtgccacc	gtggcagttt	tgttttgttt	5580
tgcttttttg	cacccagagg	caaaatgggt	ggagcactat	gcccagggga	gcccttccc	5640
aggagtccag	gggtgagcct	ctgtgatccc	ctaataatc	tcctaggaat	ggagggtaga	5700
ccgagaaaag	gctggcatag	ggggagtccg	tttcccaggt	agaagcaaga	agaagtgtca	5760
gcagaccagg	tgagcgtggg	tgccagtggg	gttcttggga	gcttcaagga	agcaaggaac	5820
gctccctcct	tctctcctg	gtctttctct	atgggacctc	gtaaataatt	actgcagcca	5880
cctgaggctg	gaaaaccaact	ccaggtgggg	gaggagagag	tttagttttc	ttgctcctat	5940
tttctctctc	ctggagacct	ccctctctcg	gctttacaaa	gacacagata	caccccgccc	6000
cccaaaacac	acacacacac	acacctcctt	aggctggaac	agcagagaat	agcagagaa	6060
ggagggacaa	gggggctgat	tagagccaag	aagagggagt	gaaggagagc	agagggagga	6120
gggcagccct	gtttacagto	acctggctgg	tgggggtggc	ggtgctctct	ctgaattaac	6180
cctttgagag	ctggccagga	ctctggactg	attaccccag	cctgggggtg	catccagggg	6240
ctctaggagg	taccttttgc	tctcaccct	ggatctcttt	tccttccacc	caggtttctg	6300
caggtaatgg	tggcagcagc	ctctcttaca	caaaccagc	agtggcagcc	acttctgcca	6360
acttgtaggg	gcacgtcgcc	cgtgagctg	agtggccagc	cagtgccatt	ccactccact	6420
caggttcttc	agggccagag	cccctgcacc	ctgtttgggc	tggtagctg	ggagttcagg	6480
tgggtgtctc	acacgtcctt	cagaggcccc	accaatttct	cggacacttc	tcagtgtgtg	6540
gaagctcatg	tgggcccctg	aggctcatgc	ctgggaagtg	ttgtgggtgg	ggctcccagg	6600
aggactggcc	cagagagccc	tgagatagcg	gggatcctga	actggactga	ataaaacgtg	6660
gtctcccaact	ggcgccaact	tctgatcttt	catctgtgac	ccgtgggcag	cagggcgctca	6720
gaatgtgtgt	gagggggctg	ggggaggaga	cagggaggcc	aggaggcagt	aaggagcgag	6780
tttgtttgag	aagcaggaga	tgtgaggagg	aggtgacatt	ggggagtagg	ggtggcctga	6840
ggagccacct	ctggctaacc	ctggcagcac	aagaggaagg	aggaaacgaa	acccaggcng	6900
gctttggagg	gctagcgtga	ctgggctccg	tgactgagct	ctgtgtgcca	gtggctctcc	6960
cctctcctcg	cctggcccac	gcccctcttg	cccctggcat	ggtgcccccc	agggtgctct	7020
attcttagct	gtccgggtgt	gaagtaaatc	cttgggcagt	gataacagcc	cagagtcaac	7080
agggttgaga	taagcagagg	ctgggtcaga	tcggggcgct	ggcaccaggc	ccagccccct	7140
cctgacccc	ggctncccc	ccagcctgct	gcccctgggg	tggntccac	aacaccctgg	7200
gaatggggaa	gtgggttctg	ttccctgacc	cctttggccc	aggcacgttg	cctgtccctc	7260
gaccgcattc	ccccagggcc	tgtgctgcag	gcctggaagc	cctgattggg	gcctgccacc	7320
agcagccaga	gagctatgtt	ccctggcagc	tgtgatgcgc	tcaggccggg	ccaggacacg	7380
tgtggcagga	ggcttagagc	acctgcctgg	ggccttctc	tctcaggcac	cagatccatt	7440
ggttgcctct	gcctagaacc	acagcctagc	accctgctc	cctcccgct	accacaccca	7500

16

```

gcacagaaac tcacaggaat gattgcgctc agggaaggca gagatgtgcc tggcatcaca 7560
gtttattgtt tataaaccat gacaataaca gctgttgctc agcacaggcc tagcagagcc 7620
cactgcaggg ggacggcagc gggcaccaga ggccttgctc ggccaaccc aatgggaaca 7680
cccagactca gctgggtccc caaggagac ttggcacatt ggcatgggtg tgggacaggt 7740
aaagcatgca agagggagaa gagggacata aggggcatgc ggctgcgggg tgttgggacc 7800
caaataaata aagcaggatg acagggtccc cttcccctca ccaggaatgc ctgacagcgt 7860
ccagccccc aaacctgcctg tcccaggct gtagttcagc atcaacaggg caggagcgtt 7920
ggcagggcaa gggcagagct ggagatcatg cccagtnttc caggtgccct cctcccaat 7980
cagcctgggg ggcacaggac agggatggag aaggggctct ctccatggct tgggtaacat 8040
gccaaaggca ggtcataggg cagactcagt ggggggtggg gcctggctaa caagcaatgg 8100
agagaacggg ggccatccag agaggttggc agaagagagc ccctgggtca agagaaaact 8160
ttggggaaga caagacacgg gagaag

```

<210> 20
 <211> 730
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (26)...(718)

```

<400> 20
cctccccacc catttcacca ccacc atg aca cag ggc acc cag tct cct ttc 52
                               Met Thr Pro Gly Thr Gln Ser Pro Phe
                               1                               5

ttc ctg ctg ctg ctc ctc aca gtg ctt aca gtt gtt aca ggt tct ggt 100
Phe Leu Leu Leu Leu Leu Thr Val Leu Thr Val Val Thr Gly Ser Gly
10                               15                               20                               25

cat gca agc tct acc cca ggt gga gaa aag gag act tcg gct acc cag 148
His Ala Ser Ser Thr Pro Gly Gly Glu Lys Glu Thr Ser Ala Thr Gln
30                               35                               40

aga agt tca gtg ccc agc tot act gag aag aat gct atc cca gca ccg 196
Arg Ser Ser Val Pro Ser Ser Thr Glu Lys Asn Ala Ile Pro Ala Pro
45                               50                               55

act act acc aag agc tgc aga gag aca ttt ctg aaa tgg cca gga tct 244
Thr Thr Thr Lys Ser Cys Arg Glu Thr Phe Leu Lys Trp Pro Gly Ser
60                               65                               70

gtg gtg gta caa ttg act ctg gcc ttc cga gaa ggt acc atc aat gtc 292
Val Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val
75                               80                               85

cac gac gtg gag aca cag ttc aat cag tat aaa acg gaa gca gcc tct 340
His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser
90                               95                               100                               105

cga tat aac ctg acg atc tca gac gtc agc gtg agt gat gtg cca ttt 388
Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe
110                               115                               120

cct ttc tct gcc cag tct ggg gct ggg gtg cca ggc tgg ggc atc gcg 436
Pro Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala
125                               130                               135

```

ctg ctg gtg ctg gtc tgt gtt ctg gtt gcg ctg gcc att gtc tat ctc 484
 Leu Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu
 140 145 150

 att gcc ttg gct gtc tgt cag tgc cgc cga aag aac tac ggg cag ctg 532
 Ile Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu
 155 160 165

 gac atc ttt cca gcc cgg gat acc tac cat cct atg agc gag tac ccc 580
 Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro
 170 175 180 185

 acc tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc gat cgt 628
 Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg
 190 195 200

 agc ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc ctc tct 676
 Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser
 205 210 215

 tac aca aac cca gca gtg gca gcc act tct gcc aac ttg tag gggcacgtcg 728
 Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu
 220 225 230

 cc 730

<210> 21
 <211> 177
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (74)...(177)

<400> 21
 ccgctccacc tctcaagcag ccagcgccctg cctgaatctg ttctgcccc tccccaccca 60
 ttccaccacc acc atg aca ccg ggc acc cag tct cct ttc ttc ctg ctg 109
 Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu
 1 5 10

 ctg ctc ctc aca gtg ctt aca ggt gga gaa aag gag act tcg gct acc 157
 Leu Leu Leu Thr Val Leu Thr Gly Gly Glu Lys Glu Thr Ser Ala Thr
 15 20 25

 cag aga agt tca gtg ccc ag 177
 Gln Arg Ser Ser Val Pro
 30

<210> 22
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22

gaacagattc aagcagccag

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23

cccggtgtca tgggtggtgt

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24

gtgcccgggtg tcatggtggt

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25

gaaaggagac tgggtgccccg

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26

ctgtaacaac tgtaagcact

20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27
acctgtaaca actgtaagca 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28
tcagtagagc tgggcactga 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29
gcattcttct cagtagagct 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30
agcattcttc tcagtagagc 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31

tggtcatact cacagcattc

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32

ctgctggtca tactcacagc

20

<210> 33

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33

gctggagagt acgctgctgg

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34

tgggaccgag gtgacatcct

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35

gtgacattgt ggactggagg

20

<210> 36

<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36
gaggtgacat tgtggactgg 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 37
tgaggccgag gtgacattgt 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38
gtggtaggag tatcagagtg 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39
gcaagggtgg taggagtatc 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40
ggcatcagtc ttggtgctat 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41
gagaccccag tagacaactg 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42
tcttcagag aggaattaaa 20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43
aatgtctctc tgcagctctt 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44
tcagaaatgt ctctctgcag 20

<210> 45
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 45
tctgcaaaaa catttcagaa 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46
gtttataaat ctgcaaaaac 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47
attggagagg cccagaaaac 20

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48
taatattgga gaggccaga 20

<210> 49
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49
gaacttaata ttggagaggc 20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50
agatcctggc ctgaacttaa 20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51
cacagatcct ggctgaact 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52
acgtcgtgga cattgatggt 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 53
gttatatcga gaggctgctt 20

<210> 54
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54

atcgtcaggt tatatcgaga

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55

gcacatcact cacgctgacg

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56

ggcagagaaa ggaaatggca

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57

gacagacagc caaggcaatg

20

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58

ctgcccgtag ttcttttcggc 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59
tggaagatg tccagctgcc 20

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60
gctacgatcg gtactgctag 20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61
aggctgctgc caccattacc 20

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62
aagttggcag aagtggtgc 20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63

ctacaagttg gcagaagtgg

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 64

acgtgcccct acaagttggc

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65

gctcagaggg cgacgtgcc

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66

ctggccactc agctcagagg

20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67

actggctggc cactcagctc

20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68
ggaatggcac tggctggcca 20

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 69
ggagtggaat ggcactggct 20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 70
aggaattaaa agcattottc 20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 71
cagtagacaa agcattottc 20

<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 72

gacagacagc catttcagaa

20

<210> 73

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 73

catcactcac tgaacttaat

20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74

tttgggtttt ccaagtaccc

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75

catagtctcc tcccaggcct

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76

cattttgcct ctgggtgcaa

20

<210> 77
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77
cagccccaga catttcagaa 20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78
ttctctctgc ccataggcct 20

<210> 79
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79
gggtctttat gaaggaaaaa 20

<210> 80
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80
acatcactca catttcagaa 20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 81

accacgtttt attcagtcca

20

<210> 82

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 82

gctgtggtag ctgtaagcac

20

<210> 83

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 83

gtgctgggat agcattcttc

20

<210> 84

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 84

agagtcaatt gtaccaccac

20

<210> 85

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 85

ttttctccac ctgtaagcac

20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 86
cctgtaacaa ctgttgcggg 20

<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 87
tgaccagaac ctgtaacaac 20

<210> 88
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 88
tctccttttc tccacctggg 20

<210> 89
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 89
ctcagtagag ctgggcactg 20

<210> 90
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 90

tcatactcac agcattcttc

20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 91

agagcctgag gccgaggtga

20

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 92

gaccccagta gacaactggg

20

<210> 93

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 93

aggaattaaa ctggaggttt

20

<210> 94

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 94

gtgctgggat cttccagaga

20

<210> 95

<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 95
atcctggcct ggtcacaggg 20

<210> 96
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 96
cagccccaga ctgggcagag 20

<210> 97
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 97
ggcccctttc ttccatagtc 20

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 98
ccacctggag tggttttcca 20

<210> 99
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 99
aaagccgaga gagggaggtc

20

<210> 100
<211> 336
<212> DNA
<213> Homo sapiens

<220>

<400> 100
accaccacca tgacaccggg caccaggtct cctttcttcc tgetgctgct cctcacagtg 60
cttacagcta ccacagcccc taaaccgcga acagttgtta caggttctgg tcatgcaagc 120
tctaccccag gtggagaaaa ggagacttgc gctaccaga gaagttcagt gccagctct 180
actgagaaga atgctgtgag tatgaccagc agcgtactct ccagccacag ccccggttca 240
ggctcctcca ccactcaggg acaggatgtc actctggccc cggccacgga accagcttca 300
ggttcagctg ccacctgggg acaggatgtc acctcg 336

<210> 101
<211> 518
<212> DNA
<213> Homo sapiens

<220>

<400> 101
gcgctgcct gaatctgttc tgccccctcc ccaccattt caccaccacc atgacaccgg 60
gcaccagctc tcctttcttc ctgctgctgc tcctcacagt gcttacagct accacagccc 120
ctaaaccgc aacagttgtt acaggttctg gtcatgcaag ctctaccca ggtggagaaa 180
aggagacttc ggctaccag agaagttcag tgcccagctc tactgagaag aatgctgtga 240
gtatgaccag cagcgtactc tccagccaca gcccggttc aggtcctcc accactcagg 300
gacaggatgt cactctggcc ccggccacgg aaccagcttc aggttcagct gccacctggg 360
gacaggatgt cacctcggtc ccagtcacca ggccagccct gggctccacc accccgccag 420
cccacgatgt cacctcagcc ccggacaaca agccagcccc gggctccacc gccccccag 480
cccacggtgt cacctcggcc ccggacacca ggccggcc 518

<210> 102
<211> 3343
<212> DNA
<213> Homo sapiens

<220>

<400> 102
gagtcctgg ccagtggtgg agagtggcaa ggaaggaccc tagggttcat cggagcccag 60
gtttactccc ttaagtggaa atttcttccc ccactccct ccttggttt ctccaaggag 120
ggaacccag gctgctggaa agtccggctg gggcggggac tgtgggtttc agggtagaac 180
tgctgtgga acgggacagg gagcggttag aagggtggg ctattccggg aagtgggtgt 240
ggggggaggg agccaaaac tagcacctag tccactcatt atccagccct cttatttctc 300
ggcgctctct gcttcagtg acccggggag ggcggggaag tggagtggga gacctagggg 360
tgggttccc gaccttgctg tacaggacct cgacctagct ggctttgttc cccatcccca 420
gttagttgtt gccctgaggc taaaactaga gccaggggc cccaagttcc agactgccc 480
tccccctcc ccggagcca gggagtgtt ggtgaaagg ggaggccagc tggagaagaa 540
acgggtagtc aggggttgca gcattagagc ccttgtagcc ctagccagc aatgggttga 600
gagagaagag tagagtaggg aggggggtt gtcacctgtc acctgctcgg ctgtgcctag 660
ggcgggcggg ggggagtgg gggaccggta taaagcggt ggcgctgtg cccgctccac 720
ctctcaagca gccagcgcct gctgaatct gtctgccc ctccccacc atttcaccac 780
caccatgaca ccgggcaccc agtctcctt ctctctgct ctgctcctca cagtgttac 840

```

aggtgagggg caccaggttg ggagtgggct gccctgctta ggtggtcttc gtggtctttc 900
tgtgggtttt gctccctggc agatggcacc agaagttaag gtaagaattg cagacagagg 960
ctgccctgtc tgtgccagaa ggaggagag gctaaggaca ggctgagaag agttgcccc 1020
aaccctgaga gtgggtacca ggggcaagca aatgtcctgt agagaagtct agggggaaga 1080
gagtagggag agggaaggct taagagggga agaaatgcag gggccatgag ccaaggccta 1140
tgggcagaga gaaggaggct gctgcaggaa ggaggcggcc aaccagggg ttactgaggc 1200
tgcccactcc ccagtcctcc tggattatt tctctggtgg ccaggcttat attttcttct 1260
tgctcttatt tttccttcat aaagacccaa ccctatgact ttaacttctt acagctacca 1320
cagcccctgg gcccgaaca gttgttacag gttctggtca tgcaagctct accccagggtg 1380
gagaaaagga gaactcggct acccagagaa gttcagtgcc cagctctact gagaagaatg 1440
ctgtgagtat gaccagcagc gtactctcca gccacagccc cggttcaggc tcctccacca 1500
ctcagggaca ggatgtcact ctggccccgg ccacggaacc agcttcagggt tcagctgcca 1560
cctggggaca ggatgtcacc tcggctcccag tcaccaggcc agccctgggc tccaccacc 1620
cgccagccca cgatgtcacc tcagccccgg acaacaagcc agccccgggc tccaccggcc 1680
ccccagccca ggggtgtcacc tcggccccgg agaccaggcc gccccgggc tccaccggcc 1740
ccccagccca tgggtgtcacc tcggcgccgg acaacaggcc cgcttgggcg tccaccggcc 1800
ctccagtcca caatgtcacc tcggcctcag gctctgcac aggtcagct tctactctgg 1860
tgcacaacgg cacctctgcc agggctacca caaccccagc cagcaagagc actccattct 1920
caattcccag ccaccactct gatactccta ccacccttg cagccatagc accaagactg 1980
atgccagtag cactcaccat agcacggtac ctctctcac ctctccaat cacagcactt 2040
ctccccagtt gtctactggg gtctctttct ttttctgtc ttttcacatt tcaaacctcc 2100
agtttaattc ctctctggaa gatcccagca ccgactacta ccaagagctg cagagagaca 2160
tttctgaaat ggtgagtatc ggcttttct tccccatgct cccctgaagc agccatcaga 2220
actgtccaca ccctttgcat caagcctgag tcttttccct ctaccccag tttttgcaga 2280
tttataaaca aggggtttt ctgggcctct ccaatattaa gttcaggtag agttctgggt 2340
gtggaccagc tgtggtggtt ggagggttg gtggtggtca tgagccgtag ggagggactg 2400
gtgcacttaa ggttggggga agagtgtga gccagagctg ggaccctgg ctgaagtgcc 2460
catttccctg tgaccaggcc aggatctgtg gtggtacaat tgactctggc cttccgagaa 2520
ggtaccatca atgtccacga cgtggagaca cagttcaatc agtataaac ggaagcagcc 2580
tctcgatata acctgacgat ctcaagacgt cagcggtag gctacttccc tgctgcagcc 2640
agcaccatgc cggggcccc ctcttccag tgtctgggtc cccgctcttt ccttagtget 2700
ggcagcggga ggggcgcctc ctctgggaga ctgcccagc cactgctttt ccttttagtg 2760
agtgtgtgc catttcttt ctctgaccag ctggggctg gggtgccagg ctggggcatc 2820
gcgctgctgg tgctggtctg tgttctggtt gcgctggcca ttgtctatct cattgccttg 2880
gtgagtgcag tccctggccc tgatcagagc ccccggtag aaggcactcc atggcctgcc 2940
ataacctct atctcccag gctgtctgtc agtgccgccc aaagaactac gggcagctgg 3000
acatctttcc agcccggtat acctaccatc ctatgagcga gtacccacc taccacacc 3060
atgggcgcta tgtgcccta gcagtaccga tcgtagcccc tatgagaagg tgagattggg 3120
ccccacaggc aggggaagca gaggttttg ctgggcaagg attctgaagg gggtagcttg 3180
aaaacccaaa gagcttgga gaggtgagaa gtggcgtgaa gtgagcaggg gagggctggc 3240
aaggatgagg ggcagaggtc agaggagttt tgggggacag gcctgggagg agactatgga 3300
agaaaggggc ccctcaaaag ggagtgcacc actgccagaa ttc 3343

```

<210> 103

<211> 859

<212> DNA

<213> Homo sapiens

<220>

<400> 103

```

cctccccacc catttcacca ccaccatgac accgggcacc cagtctcctt tcttctgtct 60
gctgctcctc acagtgttta cagttgttac aggttctggt catgcaagct ctacccagg 120
tgagaaaaag gagacttcgg ctaccagag aagttcagtg ccagctcta ctgagaagaa 180
tgctttgtct actggggtct ctttctttt cctgtctttt cacatttcaa acctccagt 240
taattcctct ctggaagatc ccagaccga ctactacca gagctgcaga gagacattt 300
tgaaatgttt ttgcagattt ataaacaagg gggttttctg ggctctcca atattaagt 360
caggccagga tctgtggttg tacaattgac tctggccttc cgagaaggta ccatcaatg 420
ccacgacgtg gagacgcagt tcaatcagta taaaacggaa gcagcctctc gatataacct 480

```

```

gacgatctca gacgtcagcg tgagtgatgt gccatttcct ttctctgccc agtctggggc 540
tggggtgcca ggctggggca tcgcgctgct ggtgctggtc tgtgttctgg ttgcgctggc 600
cattgtctat ctcatcgctt tggctgtctg tcagtgccgc cgaaagaact acgggcagct 660
ggacatcttt ccagcccggtg atacctacca tcctatgagc gagtacccca cctaccacac 720
ccatggggcg tatgtgcccc ctagcagtag cgatcgtagc ccctatgaga cggtttctgc 780
aggtaatggt ggcagcagcc tctcttacac aaaccagca gtggcagcca cttctgcca 840
ctttagggg cactgcgc 859

```

<210> 104

<211> 204

<212> DNA

<213> Homo sapiens

<220>

<400> 104

```

ccgctccacc tctcaagcag ccagcgctg cctgaatctg ttctgcccc tccccacca 60
tttcaccacc accatgacac cgggcaccca gtctccttc ttctgctgc tgcctctcac 120
agtgttaca ggttctggtc atgcaagctc taccacaggt ggagaaaagg agacttcggc 180
taccagaga agttcagtc ccag 204

```

<210> 105

<211> 556

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> 5

<223> n = A,T,C or G

<400> 105

```

acgnggaag agagtaggga gagggaaggg ttaagagggg aagaaatgca ggggccatga 60
gccaaggcct atgggcagag agaaggaggg tgctgcaggg aaggaggcgg ccaaccaggt 120
ggttactgag gctgccact cccagtcct cctggtatta ttctctggt ggccagagct 180
tatattttct tcttgctctt atttttcctt cataaagacc caaccctatg actttaactt 240
cttacagcta ccacagcccc taaaccgcga acagttgtta cgggttctgg tcatgcaagc 300
tctaccccag gtggagaaaa ggagacttcg gctaccaga gaagttcagt gccagctct 360
actgagaaga atgctgtgag tatgaccagc agcgtactct ccagccacag ccccggttca 420
ggctcctcca ccactcaggg acaggatgtc actctggccc cggccacgga accagcttca 480
ggttcaagct gccacctggg acaggatgtc accttcgtcc cagtcaccag gccagccctg 540
ggctccacca cccgc 556

```

<210> 106

<211> 772

<212> DNA

<213> Homo sapiens

<220>

<400> 106

```

gacctctcaa gcagccagcg cctgcctgaa tctgttctgc cccctcccca cccatttcac 60
caccaccatg acaccgggca cccagtcctc ttcttctctg ctgctgctcc tcacagtgt 120
tacagctacc acagccccta aaccgcgaac agttgttacg ggttctggtc atgcaagctc 180
taccacaggt ggagaaaagg agacttcggc taccagaga agttcagtc ccagctctac 240
tgagaagaat gcttttaatt cctctctgga agatcccagc accgactact accaagagct 300
gcagagagac atttctgaaa tgtttttgca gatttataaa caagggggtt ttctgggcct 360
ctccaatatt aagttcaggc caggatctgt ggtgggtacaa ttgactctgg ccttccgaga 420

```



```

aggtaccatc aatgtccacg acgtggagac acagttcact cagtataaac ggaagcagcc 480
tctcgatata acctgacgat ctcagacgtc agcgtgagtg atgtgccatt tcctttttctc 540
tgcccagttc ggggctgggg ttgccaggct ggggcatcgc ggctgctggg gctgggtctg 600
tgtcctgggt gcgctggcca ttgtctatct cattgccttg cgtgttcctg tcagtgccgc 660
ggacagaaca cgggcccgtg gacctctttc ccgccggga tacctacatc ctttgagggg 720
agtccccact acacaccatg gggggattgt gcccttagc gttccgatcg ac 772

```

<210> 107

<211> 635

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> 472, 482

<223> n = A,T,C or G

<400> 107

```

ggctggggtg ccaggctggg gcatcgcgct gctggtgctg gtctgtgttc tggttgcgct 60
ggccattgtc tatctcattg ccttggtgtg ctgtcagtgc cgcgaaaga actacgggca 120
gctggacatc tttccagccc gggataccta ccacacctatg agcgagtacc ccacctacca 180
caccatggg cgctatgtgc cccctagcag taccgatcgt agcccctatg agaagggtgag 240
attgggcccc acaggccagg ggaagcagag ggtttggtg ggcaaggatt ctgaaggggg 300
tacttggaag aoccaaagag cttggaagag gtgagaagtg gcgtgaagtg agcaggggag 360
ggcctggcaa ggatgagggg cagagggtcag aggagttttg ggggacaggc ctgggaggag 420
actatggaag aaaggggccc tcaagaggga gtggccccac tgccagaatt cntaaaagat 480
cnttggccgt ccacattcat gctggctggc gctggctgaa ctgggtgccac cgtggcagtt 540
ttgttttgtt ttgttttttt gcaccagag gcaaaatggg tggagcacta tgcccagggg 600
agcccttccc gaggagtcca aggggtgagc ttttg 635

```